Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1790363 | 0.98 | LMNA (0.52) | MAPTLMNAESR1PGRCHRM2 | |
| SCHEMBL16022195 | 0.95 | HSD17B10 (0.51) | MAPTLMNAESR1PGRCHRM2 | |
| SCHEMBL15382242 | 0.91 | MAPT (0.55) | MAPTLMNAESR1PGRCHRM2 | |
| SCHEMBL4443112 | 0.91 | LMNA (0.55) | MAPTLMNAESR1PGRCHRM2 | |
| SCHEMBL7510922 | 0.87 | HAO1 (0.49) | MAPTSMN1; SMN2ALDH1A1HDAC1HDAC8 | |
| SCHEMBL238310 | 0.85 | HDAC8 (0.49) | MAPTSMN1; SMN2ALDH1A1HDAC1HDAC8 | |
| SCHEMBL14877967 | 0.84 | ESR2 (0.55) | MAPTLMNAESR1PGRCHRM2 | |
| SCHEMBL1089780 | 0.83 | KMT2A (0.49) | MAPTSMN1; SMN2ALDH1A1HDAC1HDAC8 | |
| SCHEMBL4359580 | 0.83 | ESR2 (0.56) | MAPTLMNAESR1PGRCHRM2 | |
| SCHEMBL14774960 | 0.83 | SMN1; SMN2 (0.50) | MAPTLMNASMN1; SMN2ALDH1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2800738-B1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NOVARTIS AG (CH) | 2020-04-08 | — | — | EP | disclosed |
| US-10370388-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2019-08-06 | — | — | US | disclosed |
| EP-2249426-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEM CORP (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-05-25 | — | — | US | disclosed |
| US-9624243-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20160209561-A1 | Photochromic Articles That Include Photochromic-Dichroic Materials | TRANSITIONS OPTICAL, INC. | 2016-07-21 | — | — | US | disclosed |
| CN-105762402-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | 三菱化学株式会社 | 2016-07-13 | — | — | CN | disclosed |
| US-9206151-B2 | Method of preparing fused ring indeno compounds | TRANSITIONS OPTICAL, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| CN-103078137-B | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORP. (JP) | 2015-09-16 | — | — | CN | disclosed |
| US-9083058-B2 | Nonaqueous electrolytic solution and nonaqueous-electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-07-14 | — | — | US | disclosed |
| US-8846254-B2 | — | — | 2014-09-30 | — | — | US | disclosed |
| US-20140134481-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-05-15 | — | — | US | disclosed |
| WO-2013102242-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-07-11 | — | — | WO | disclosed |
| CN-103078137-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | MITSUBISHI CHEM CORP | 2013-05-01 | — | — | CN | disclosed |
| US-20120308883-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120219854-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20110123871-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY | MITSUBISHI CHEMCIAL (JP) | 2011-05-26 | — | — | US | disclosed |
| CN-101960662-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | MITSUBISHI CHEM CORP | 2011-01-26 | — | — | CN | disclosed |
| EP-2249426-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | Mitsubishi Chemical Corporation (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-6300499-B1 | α1-adrenergic receptor antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370388-B2 | Heterocyclic compounds and methods of their use | AGTR2, AGTR1, BDKRB2 | MAPT 3922/4885LMNA 4301/4885ESR1 1693/4885 |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | AGTR2, AGTR1, BDKRB2 | MAPT 3894/4885LMNA 4330/4885ESR1 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.